iloprost (ventavis) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Iloprost is a second generation structural analog of prostacyclin (PGI) with about ten-fold greater potency than the first generation stable analogs, such as carbaprostacyclin. Iloprost binds with equal affinity to human prostacyclin (Prostanoid IP) and prostaglandin EP1 receptors. Iloprost constricts the ilium and fundus circular smooth muscle as strongly as prostaglandin E2 (PGE2) itself. Iloprost inhibits the ADP, thrombin, and collagen-induced aggregation of human platelets. In whole animals, iloprost acts as a vasodilator, hypotensive, antidiuretic, and prolongs bleeding time. All of these properties help to antagonize the pathological changes that take place in the small pulmonary arteries of patients with pulmonary hypertension. Used for the treatment of pulmonary arterial hypertension.   NCATS

Chemistry

  • SMILES: CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2C\C(C[C@H]12)=C/CCCC(O)=O
  • InChIKey: HIFJCPQKFCZDDL-ACWOEMLNSA-N
  • Mol. Mass: 360.4871
  • ALogP: 3.54
  • ChEMBL Molecule:
    iloprost  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$9.0346

United States

$101.1077 - $134.6997
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

ciloprost | endoprost | illoprost | ilomedin | iloprost | ventavis | zk-00036374 | zk36374 | zk 36374 | zk-36374

Organizations (68)

Research & Development (67)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (39)

Approved Indications (2)


 

Hypertension, Pulmonary (approved 2004)

Pulmonary Arterial Hypertension

Experimental Indications - Clinical Trial Phases 1-4 (39)


 

Acute Lung Injury (Phase 1)

Angioplasty, Balloon, Coronary (Phase 2/Phase 3)

Arterial Occlusive Diseases (Phase 2)

Arteriosclerosis (Phase 2)

Asthma (Early Phase 1)

Bronchi (Phase 2)

Carcinoma (Phase 2)

Coronary Angiography (Phase 2/Phase 3)

COVID-19 (Phase 2)

Diabetes Mellitus (Phase 2)

Healthy Volunteers (Phase 1/Phase 2)

Heart Arrest (Phase 2)

Heart Defects, Congenital (Phase 1/Phase 2)

Heart Failure, Diastolic (Phase 4)

Hypertension (Phase 4)

Hypertension, Pulmonary (Phase 4)

Hypertrophy, Left Ventricular (Phase 2)

Lung Diseases (Phase 1/Phase 2)

Lung Neoplasms (Phase 2)

Multiple Organ Failure (Phase 2)

Myocardial Infarction (Phase 1/Phase 2)

Peripheral Arterial Disease (Phase 4)

Peripheral Nerve Injuries (Phase 2)

Persistent Fetal Circulation Syndrome (Phase 1/Phase 2)

Pneumonia (Phase 2)

Precancerous Conditions (Phase 2)

Pulmonary Arterial Hypertension (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Pulmonary Fibrosis (Phase 2/Phase 3)

Raynaud Disease (Phase 3)

Renal Insufficiency, Chronic (Phase 2/Phase 3)

Respiratory Distress Syndrome (Phase 3)

Respiratory Insufficiency (Phase 2)

Sarcoidosis (Phase 4)

Scleroderma, Systemic (Phase 3)

Sclerosis (Phase 3)

Shock (Phase 3)

Shock, Septic (Phase 2/Phase 3)

Shoulder Fractures (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 70
  • # of Trial Organizations: 67

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue